A single viral platform shows promise across infectious disease and cancer ReiThera’s gorilla-derived adenovirus vector is helping advance vaccines and therapies for COVID-19, HIV, Ebola, and even cancer. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/a-single-viral-platform-shows-promise-across-infectious-disease-and-cancer-17103?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9AVNke2GsjfUAH4klAHUbDwd9KUHvUb7XOLqpTqqD969vkKpbA_anyAowbUKoDN2KhFojXwlgJo1VRt3JP_tvUWDypmA&_hsmi=433938578&utm_content=433938578&utm_source=hs_email At Advanced Therapies 2026, DDN spoke with Claudio Panzarella, Head of Business Development, and Angelo Raggioli, Head of Technology Development, at ReiThera, about how the company’s early COVID-19 vaccine efforts shaped its current scientific programs, including the gorilla adenovirus (GRAd) platform, ongoing HIV vaccine trials, and the potential for oncology therapeutics.